Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With <i>EGFR</i> Mutation

ZHANG Chan-yuan; FENG Wei-neng

doi:10.12019/j.issn.1671-5144.202502013

ZHANG Chan-yuan, FENG Wei-neng. Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 27-30. DOI: 10.12019/j.issn.1671-5144.202502013

Citation:

ZHANG Chan-yuan, FENG Wei-neng. Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 27-30. DOI: 10.12019/j.issn.1671-5144.202502013

Citation:

ZHANG Chan-yuan, FENG Wei-neng. Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 27-30. DOI: 10.12019/j.issn.1671-5144.202502013

Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation

Graphical Abstract

Graphical Abstract

Abstract

FullText(HTML)

References (22)

Amivantamab Combined With Lazertinib Opens a New Pattern of Treatment for Advanced NSCLC With EGFR Mutation

Graphical Abstract

Catalog

Export File

Citation

Format

Content